Dasatinib, a dual Src family kinase and Abl inhibitor, is being tested clinically for the treatment of prostate cancer bone metastasis. Bidirectional interactions between osteoblasts and prostate cancer cells are critical in the progression of prostate cancer in bone, but the effect of dasatinib on osteoblasts is unknown. We found that dasatinib inhibited proliferation of primary mouse osteoblasts isolated from mouse calvaria and the immortalized MC3T3-E1 cell line. In calvarial osteoblasts from Col-luc transgenic mice carrying osteoblast-specific Col1a1 promoter reporter, luciferase activity was inhibited. Dasatinib also inhibited fibroblast growth factor-2-induced osteoblast proliferation, but strongly promoted osteoblast differentiation, as reflected by stimulation of alkaline phosphatase activity, osteocalcin secretion and osteoblast mineralization. To determine how dasatinib blocks proliferative signaling in osteoblasts, we analyzed the expression of a panel of tyrosine kinases, including Src, Lyn, Fyn, Yes and Abl, in osteoblasts. In the Src family kinases, only Src was activated at a high level. Abl was expressed at a low level in osteoblasts. Phosphorylation of Src-Y419 or Abl-Y245 was inhibited by dasatinib treatment. Knockdown of either Src or Abl by lenti-shRNA in osteoblasts enhances osteoblast differentiation, suggesting that dasatinib enhances osteoblast differentiation through inhibition of both Src and Abl.
Introduction
Prostate cancer metastasis to bone is the major cause of mortality in afflicted patients . As a result, treatment strategies targeting bone metastasis have been one of the major focuses in prostate cancer therapy.
One of the unique characteristics of bone metastasis from prostate cancer is that the tumor lesions tend to be osteoblastic rather than osteolytic, and this phenomenon led to the hypothesis that bidirectional interactions between prostate cancer cells and osteoblasts are critical in the growth of metastatic cells in the bone (Logothetis and Lin, 2005) . In support of this hypothesis, several investigations showed that prostate cancer cells secrete proteins that stimulate osteoblast proliferation and/or differentiation. These factors include ET-1 (Nelson et al., 1995 (Nelson et al., , 1999 , BMP-6 (Autzen et al., 1998; Dai et al., 2005) , BMP-7 (Masuda et al., 2003) , p45-sErbB3 (Vakar-Lopez et al., 2004; Chen et al., 2007; Lin et al., 2008) and fibroblast growth factor 9 (FGF-9) (Li et al., 2008) . A number of observations also showed that increases in osteoblast proliferation and/or differentiation lead to secretion of factors, for example, osteonectin (Jacob et al., 1999; Chen et al., 2007) , that enhance the survival of prostate cancer cells in bone. Together, these observations suggest that therapy targeting both prostate cancer cells and osteoblasts will be effective in halting (or maybe retarding) prostate cancer progression in bone.
Dasatinib (BMS-354825) is a dual Src family kinase (SFK) and Abl kinase inhibitor that inhibits autophosphorylation of Src family nonreceptor protein tyrosine kinases, including Src, Lyn, Yes and Lck (Lombardo et al., 2004) , and Abl (Shah et al., 2004) . The Src family protein tyrosine kinases are involved in several cancer types, including colorectal (Cartwright et al., 1989 (Cartwright et al., , 1990 Talamonti et al., 1993) and pancreatic (Ito et al., 2003; Summy and Gallick, 2003; Trevino et al., 2006) cancers. In prostate cancer, increased activity of Src has been observed in prostate cancer cells present in bone metastases (G Gallick and SH Lin, unpublished observations) , and dasatinib effectively inhibits the proliferation and invasion of the bone-metastasisderived prostate cancer cell line PC-3 (Nam et al., 2005; Park et al., 2008) , suggesting that Src family tyrosine kinases participate in the metastatic progression of prostate cancer in bone. It is interesting that Park et al. (2008) showed that treating PC-3 cells with dasatinib led to the inhibition of proliferation and invasion as the result of decreased kinase activities of Lyn and Src activity, respectively. Thus, Src family members have different functions in prostate cancer progression.
Src activity is also critical to osteoclast function. Studies by Soriano et al. (1991) showed that mice with targeted disruption of the c-Src gene showed a phenotype similar to that associated with osteopetrosis. The mechanism underlying osteopetrosis arising from an Src deficiency was determined to be mainly inhibition of osteoclast maturation (Boyce et al., 1992; Lowe et al., 1993) . As expected, dasatinib inhibits osteoclast function (Brownlow et al., 2009) . Whether Src has an effect on osteoblasts in c-Src-knockout mice was not known until Marzia et al. (2000) reported that reduction or deletion of Src expression enhances osteoblast differentiation. However, it is unclear whether other SFKs are expressed in osteoblasts, whether they participate in bone formation and whether SFK/Abl inhibitors in clinical trial affect these functions.
Owing to its effectiveness in halting prostate cancer cell proliferation and invasion, dasatinib is being tested as an inhibitor of progression of prostate cancer bone metastasis in clinical trials (Kopetz et al., 2007; Araujo and Logothetis, 2009) . Because osteoblasts are critical to the progression of prostate cancer in bone, it is important to examine the specific or overlapping roles of Src family members in osteoblast function. Dasatinib inhibits both SFKs and Abl, so its effects on osteoblasts may depend on the expression and activation of SFKs and Abl in those cells. Interestingly, Li et al. (2000) showed that mice deficient in Abl are osteoporotic due to delayed maturation of osteoblasts, in contrast to the osteopetrotic phenotype resulting from an Src deficiency.
In this study, we examined the effect of dasatinib on osteoblast proliferation and differentiation. We found that dasatinib suppresses the proliferation of osteoblasts and enhances their maturation. Osteoblasts express a relatively high level of Src, Lyn and Fyn, but a very low or undetectable level of Yes. Among Src, Lyn and Fyn, only Src is phosphorylated in osteoblasts, and dasatinib inhibited its phosphorylation at Y419. Knockdown of either Src or Abl in osteoblasts enhances osteoblast differentiation. Together, our study results suggest that dasatinib decreases osteoblast proliferation and enhances its differentiation by inhibiting both Src and Abl.
Results

Dasatinib treatment inhibits proliferation of PMOs
The process of bone formation includes initial osteoblast proliferation followed by increased alkaline phosphatase activity, deposition of extracellular matrix and mineralization (Stein and Lian, 1993; Aubin, 1998) . We first examined the effects of dasatinib on osteoblast proliferation. Primary mouse osteoblasts (PMOs) isolated from calvaria of 2-to 5-day-old mice were treated with various concentrations of dasatinib. As shown in Figure 1 , at a concentration as low as 50 nM, dasatinib caused an approximate 50% reduction of osteoblast cell numbers when the osteoblasts were cultured in the absence (0.1% bovine serum albumin, BSA) or presence of serum (10% fetal bovine serum, FBS)-containing medium for 72 h (Figures 1a and b) . We further examined the time course of dasatinib on PMOs proliferation. As shown in Figure 1c , dasatinib treatment led to a time-dependent inhibition of PMOs proliferation.
Effects of dasatinib on proliferation of PMOs from Col-luc mice Although calvarial osteoblasts isolated from 2-to 5-dayold mice are frequently used for measuring osteoblast activity, the digested calvaria usually contain other cell types as well (Bellows and Aubin, 1989) . Because SFKs are expressed in most cell types, including fibroblasts, the decrease we found in cell numbers might be due to the inhibition of osteoblasts, fibroblasts or both. To further confirm that dasatinib has an effect on cells of osteoblast lineage, we prepared PMOs from transgenic mice (Col-luc mice) carrying an osteoblast-specific reporter construct.
Col-luc transgenic mice were previously generated by injecting DNA construct containing the 2.3 kb Col1a1 promoter-luciferase gene into the pronuclei of fertilized mouse ova (Rossert et al., 1995; Figure 2a) . Previous studies showed that luciferase activity is specifically expressed in osteoblasts because the highest specific activity was detected in the bones (Rossert et al., 1995) . To avoid the need to genotype the mice when preparing the PMOs, we bred the Col-luc transgenic mice to homozygosity, which we confirmed by the observation that 100% of the offspring were positive for luciferase activity in their tail protein lysates when they were bred to wild-type mice (data not shown). To confirm the tissue specificity of the reporter in the Col-luc mice, we measured the luciferase activities in 4-day-old Col-luc tissues. Expression of the luciferase gene was highly tissue specific, with tibia, tooth, calvaria and tail expressing high levels of luciferase activity, whereas other tissues, including liver, lung, heart, kidney, and skin, had low or undetectable levels of luciferase activity (Figure 2b ). The bone-specific expression of the luciferase reporter gene was further confirmed by using bioluminescence imaging to detect the luciferase activity in vivo. Strong bioluminescence signals were detected in the skull and hind limbs (Figure 2b ). These data indicate that the proximal 2.3-kb Col1a1 promoter directs an osteoblast-specific expression of luciferase in the mice homozygote with Col1a1 transgene.
We examined the effect of dasatinib on the PMOs isolated from Col-luc mice. As shown in Figure 2c , treatment of Col-luc osteoblasts with dasatinib led to inhibition (B40%) of both cell numbers and luciferase activity when cultured in medium containing either 0.1% BSA or 10% FBS. We further assessed the effect of dasatinib on the proliferation of MC3T3-E1, immortalized osteoblasts that have the characteristics of preosteoblasts (Franceschi and Iyer, 1992) , and found that dasatinib inhibited MC3T3-E1 proliferation in a time-dependent manner ( Figure 3a) . Together, these results show that dasatinib suppresses osteoblast proliferation.
Dasatinib inhibits FGF-2-induced osteoblast proliferation
Fibroblast growth factors reportedly have key functions in prostate tumor progression (Dorkin et al., 1999a (Dorkin et al., , 1999b and stimulation of bone formation (Canalis et al., 1988; Globus et al., 1988; McCarthy et al., 1989; Mayahara et al., 1993; Fakhry et al., 2005) . In prostate cancer bone metastasis, FGFs secreted by metastatic prostate cancer cells may contribute to the osteoblastic phenotype of the prostate cancer bone lesion (Li et al., 2008) . Debiais et al. (2001) showed that several signaling molecules, including Src, were activated by treating immortalized human neonatal calvaria cells with FGF-2. We thus examined the effect of dasatinib on FGF-2-induced osteoblast proliferation. As shown in Figure 3b , treatment of Col-luc osteoblasts with dasatinib resulted in partial inhibition of FGF-2-induced osteoblast proliferation (FGF þ dasatinib vs FGF; Po0.05). Dasatinib also inhibited FGF-2-induced proliferation of MC3T3-E1 cells (Figure 3b ). These results suggest that dasatinib is effective in inhibiting FGF-2-induced osteogenesis.
Effect of dasatinib on differentiation of osteoblasts
Because osteoblast maturation is a balance between proliferation and differentiation, suppression of osteoblast proliferation by dasatinib may enhance differentiation. To determine the effect of dasatinib on osteoblast differentiation and/or maturation, we treated PMOs cultured in osteoblast differentiation medium with 50 nM dasatinib. The expression of osteoblast differentiation markers, that is, alkaline phosphatase, osteocalcin and mineral deposition, during the time course of differentiation was measured.
As shown in Figure 4a , treatment of PMOs with dasatinib led to stimulation of alkaline phosphatase activity, which could be detected as early as 3 days, and the stimulation reached 19 times that of the control at the late stage of differentiation ( Figure 4a ). The alkaline phosphatase activities of the control samples are also shown in the inset in Figure 4a . Similar effects were seen with MC3T3-E1 cells (Figure 4a ). However, in MC3T3-E1 cells, the increase in alkaline phosphatase activity was only about twice that of the control, possibly because MC3T3-E1 is an immortalized calvarial cell line. Treatment of PMOs with dasatinib also stimulated the expression of osteocalcin relative to the control samples (Figure 4b) , and enhanced osteoblast mineralization, as reflected in greater von Kossa staining than that in the control (Figure 4c ). Together, these observations suggest that dasatinib treatment increases the differentiation of osteoblasts.
Effect of dasatinib on SFKs in osteoblasts
We next determined the expression of dasatinib targets in osteoblasts. The kinase activity of both the SFKs and the Abl is reported to be inhibited by dasatinib (Lombardo et al., 2004; Shah et al., 2004) . Previous studies showed that deletion of Src or Abl in mice led to changes in bone phenotype (Soriano et al., 1991; Li et al., 2000) , suggesting that both kinases are involved in bone formation.
We first examined which SFK(s) have a role in osteoblast function. Treatment of PMOs and MC3T3-E1 cells with dasatinib led to inhibition of the phosphorylation of SFKs, as detected by anti-p-SFK antibody, which detects SFK proteins phosphorylated at their autophosphorylation site, indicative of their activation (Figure 5a ). The effect of dasatinib on individual SFKs was further examined by immunoprecipitation using antibodies specific to each kinase. Cell lysates from PC-3, L3.6pl, K562 and HT29 cells were used as positive controls for Src, Lyn, Fyn and Yes, respectively. All the positive controls for immunoprecipitations were run on the same gel with the immunoprecipitation samples. As shown in Figure 5b , Src was expressed and activated in MC3T3-E1 cells as determined by reactivity with the anti-p-SFK antibody. Its phosphorylation was significantly inhibited by the treatment of osteoblasts with 50 nM dasatinib. Although both Lyn and Fyn were expressed in MC3T3-E1 cells, they were not phosphorylated (Figure 5b ). The kinase Yes was not expressed at detectable levels in MC3T3-E1 cells (Figure 5b ). These results suggest that among several SFKs, only Src is expressed and present in its activated form in osteoblasts.
Effect of Src knockdown on osteoblast differentiation
To test the role of Src in osteoblasts, Src-specific lentishRNA was used to knockdown Src on PMOs. Lentivirus containing nontargeting shRNA was used as control. PMOs infected with copGFP lentivirus showed that PMOs could be transduced by lentivirus effectively (Supplementary Figure S1) . For the effect of Src knockdown on osteoblast differentiation, PMOs were infected with Src lenti-shRNA and cultured in differentiation medium for 9 or 18 days (Figure 6a ). The level of Src was reduced by about 50% in the PMOs infected with Src-specific lenti-shRNA compared with that in control shRNA-infected cells (Figure 6b) . Knockdown of Src led to an increase in alkaline phosphatase activity ( Figure  6c ), osteocalcin ( Figure 6d ) and mineralization (Figure 6e ). These observations suggest that downregulation of Src in PMOs stimulates osteoblast differentiation.
Effect of Abl knockdown on osteoblast differentiation Next, we examined the expression of Abl in osteoblasts. The expression levels of Abl in both PMOs and MC3T3-E1 cells were low and PMOs have much lower level of Abl compared with that in MC3T3-E1 cells (Figure 7a) . Treatment of PMOs and MC3T3-E1 cells with dasatinib led to inhibition of the phosphorylation of Abl at tyrosine-245, which was detected by immunoprecipitation followed with anti-p-Y245-Abl antibody (Figure 7a ). These results indicate that dasatinib inhibits Abl kinase activity.
To test the role of Abl in osteoblasts, we used Ablspecific lenti-shRNA to knock down Abl on PMOs. Treatment with Abl-specific lenti-shRNA reduced Abl level to 50% compared with that in control shRNAinfected cells (Figure 7b ). Knockdown of Abl led to an increase of alkaline phosphatase activity and osteocalcin, and a modest increase in mineralization (Figure 7c ). These observations suggest that downregulation of Abl in PMOs stimulates osteoblast differentiation. However, Abl seems to affect osteoblast differentiation to a much lesser extent compared with that from Src knockdown when the knockdown of Abl or Src was performed in the same experiment (Figure 7d ). When the PMOs were treated with both Src shRNA and Abl shRNA, the combined effects from knockdown of Src and Abl are similar to those from Src knockdown alone (Figure 7d ). Together, these observations suggest that the effect of dasatinib on osteoblast differentiation is due to the inhibition of both Src and Abl activities.
Effect of dasatinib on osteonectin expression
Previous studies have shown that osteonectin is implicated as one of the osteoblast-derived factors that stimulate prostate cancer cells (Jacob et al., 1999; Chen et al., 2007) . We thus examined whether dasatinib has an effect on osteonectin expression. We found that osteonectin expression was decreased during PMO differentiation and dasatinib treatment increased osteonectin production in the conditioned medium (Figure 8 ). We also analyzed the levels of osteonectin in the media from PMOs that had been infected with Src-or Abl-or both Src and Abl lenti-shRNAs. Western blots of osteonectin showed that knockdown of Src slightly increased osteonectin expression in the early time points (Figure 8 ). In contrast, knockdown of Abl greatly increased the production of osteonectin throughout the entire time course of differentiation. Knockdown of both Src and Abl led to increase in osteonectin levels similar to that observed by Abl knockdown alone. Thus, the stimulation of osteonectin production by dasatinib is mainly through inhibition of Abl. These studies also showed that Src and Abl have different effects on osteoblasts, suggesting that Src-specific inhibitors will have different effects from dasatinib.
Discussion
Protein tyrosine kinases are important in bone homeostasis (Soriano et al., 1991; Li et al., 2000) . Therapies that inhibit tyrosine kinase activities in the treatment of various cancer types may also have effects on bone. Such an unintended effect on bone has been reported with the use of imatinib for the treatment of chronic myelogenous leukemia or gastrointestinal stromal tumors (Berman et al., 2006) . The use of tyrosine kinase inhibitors for the treatment of prostate cancer bone metastases is particularly important because prostate cancer cells are in direct interaction with the other cells present in the bone microenvironment, especially osteoblasts. Because various nonreceptor protein tyrosine kinases (for example, Abl and Src) reportedly have different roles in the proliferation and maturation of osteoblasts, it is important both to determine which protein tyrosine kinases has direct roles in these processes and to examine the effect of dasatinib, which targets multiple tyrosine kinases, on osteoblast functions. The results of our studies showed that dasatinib suppresses the proliferation and enhances the differentiation of osteoblasts and that this effect occurs mainly through the inhibition of Src and Abl activities.
Our study results also indicate that among the several SFKs expressed in osteoblasts, Src is dominant in regulating osteoblast activity. We observed that both Lyn and Fyn are expressed in osteoblasts but are not activated (Figure 5b ), whereas Yes was not detectable (Figure 5b ). In contrast, Src is highly expressed in osteoblasts and present in the active state. Our observations are consistent with the results reported by Marzia et al. (2000) , who showed that decreased Src expression in osteoblasts using Src antisense RNA led to decreased osteoblast proliferation concomitant with increased osteoblast differentiation. Similarly, Shor et al. (2007) showed that Src is critical in various types of osteosarcoma and that dasatinib was effective in inducing apoptosis and inhibiting the migration and invasion of osteosarcoma cells (Shor et al., 2007) . Together, these observations suggest that Src has a central role in regulating osteoblast function. Li et al. (2000) showed that mice deficient in Abl are osteoporotic due to delayed maturation of osteoblasts, in contrast to the osteopetrotic phenotype that results from Src deficiency. Our studies using shRNA to knockdown Abl in vitro showed that decrease in the level of Abl stimulates osteoblast maturation as measured by expression of alkaline phosphatase and osteocalcin. The differences in the effect of Abl on osteoblast maturation may be due to compensation of the effect of Abl deletion by other mechanisms in vivo, which may not occur in the in vitro studies.
Src has been shown to be critical in osteoclast function. To address the possibility that the effect of dasatinib on osteoblast may be indirectly due to inhibition of osteoclasts contaminated in the osteoclast culture, we stained the PMOs culture for the presence of osteoclasts. We did not detect tartrate-resistant alkaline phosphatase (TRAP)-positive osteoclasts by quantitative TRAP assay (Supplementary Figure S2A) or by TRAP staining (Supplementary Figure S2B) in the PMOs. We also did not detect any osteoclast in the PMOs treated with various concentrations of RANKL (Supplementary Figure S2) . The positive controls are RAW264.7 cells induced by various concentrations of RANKL (Supplementary Figure S2) . Thus, the presence of osteoclasts, if any, is minimal in our culture condition.
Our observation that dasatinib inhibited collagen type I promoter-initiated luciferase activity in Col-luc calvarial osteoblasts raised the issue that dasatinib may inhibit osteoblast proliferation or collagen expression or both. We examined the levels of collagen type I in the osteoblasts treated with or without dasatinib using western blot analysis and found that dasatinib does not affect the levels of collagen type1 expression in the PMOs (data not shown). Thus, dasatinib inhibition of luciferase activity in Col-luc osteoblasts is due to its effect on osteoblast proliferation, not collagen expression. Consistent with this finding, dasatinib also did not affect collagen type I expression in PC3 and LNCaP prostate cancer cell lines (data not shown).
The results presented in this study show not only novel functions for Src in osteoblast function, but have implications for use of Src inhibitors in metastatic bone disease. Studies of the SFK inhibitor AZD0530 in normal volunteers showed the predicted effect of bone thickening, due to decreased osteoclast function (Hannon et al., 2009) . Koreckij et al. (2009) showed that following intratibial injection of C4-2B cells in severe combined immunodeficient mice, antitumor effect of dasatinib correlated with a 25% increase in mineral density in tibia-bearing tumors. These studies do not consider the ability of tumor cells to secrete factors affecting osteoblasts when tumors are growing in the bone. Early results from phase 1/2 clinical trials in prostate cancer patients with metastases in bone using the combination of dasatinib and docetaxel have suggested that markers of bone turnover are inhibited when prostate-specific antigen is decreased , unpublished results), however, which effects are due to dasatinib alone cannot be determined from this trial. Collectively, these results show conclusively that bone remodeling is affected by Src inhibition. However, our study results challenge the idea that the ability of Src inhibitors to affect bone remodeling is solely due to the inhibitor's effects on tumor and osteoclast functions. Rather, our study data suggest that the effect of dasatinib on osteoblasts also has a critical role in these processes. Because the quantitative and qualitative release of soluble modifiers from the tumor is likely to govern osteoblastic or osteolytic lesions, we predict that if dasatinib blocks tumor growth, secreted factors that promote osteoblast differentiation will also be inhibited. However, if the tumors themselves are not sensitive to dasatinib treatment, dasatinib may enhance osteoblastic lesions.
The results of our studies also showed that inhibition of Abl, but not Src expression by shRNA knockdown in osteoblasts, led to an increase in osteonectin expression, suggesting that Src and Abl have different effects on osteoblasts. Thus, if Src-specific inhibitors are developed, they may have different outcomes from dasatinib. Because osteonectin has been implicated as the osteoblast-derived factor that stimulates the invasion of prostate cancer cells (Chen et al., 2007) , these data imply that the effects of dasatinib on osteoblasts may promote prostate cancer progression. A phase 3 clinical trial that tests dasatinib in combination with docetaxel on prostate cancer bone metastasis is in progress. Understanding the changes in bone biomarkers and osteonectin and correlating them with the clinical outcomes will be important in future trial designs with SFK/Abl inhibitors.
Materials and methods
Isolation of osteoblasts from mouse calvaria and proliferation assay Primary mouse osteoblasts were prepared from mouse calvaria as described previously (Lin et al., 2008) . The cells were then treated with various concentrations of dasatinib for 1-4 days. Cell numbers were counted using a hemacytometer.
Col-luc transgenic mice Transgenic mice harboring a luciferase transgene under the control of the proximal 2.3-kb segments of the mouse Col1a1 promoter were generated by injecting DNA construct containing the 2.3-kb pro-a1(I) promoter-luciferase (luc) gene into the pronuclei of mouse B 6 Â D 2 F 2 fertilized ova as described elsewhere (Rossert et al., 1995) . We named these transgenic mice Col-luc mice and bred them to be homozygous for the transgene to avoid the need for genotyping them.
Measurement of reporter protein activities in Col-luc mouse tissues Tissues were dissected from 2-to 5-day-old Col-luc mice and homogenized, and the proteins were extracted with passive lysis buffer (Promega Corporation, Madison, WI, USA). Luciferase activity in the tissues was assessed using a luciferase assay kit (Promega Corporation), and the luminescence was detected with a 20/20 luminometer (Turner Biosystems, Sunnyvale, CA, USA). Results were expressed as relative luciferase units.
Bioluminescence imaging
For bioluminescence imaging, 4-day-old wild-type or Col-luc pups were injected subcutaneously with D-luciferin solution (150 mg/kg body weight). Images were acquired and analyzed using a Xenogen imaging system (Xenogen, Alameda, CA, USA).
Col-luc osteoblast proliferation assays Calvarial PMOs were plated on a 48-well cell culture dish (5 Â 10 4 cells per well) in 0.5 ml of complete medium (a-MEM medium with 10% FBS and antibiotics) overnight. Cells were then treated with the test compounds for 72 h, lysed in 1 Â passive lysis buffer (Promega Corporation) and the luciferase activities in the cell extracts were measured.
Osteoblast differentiation assays
Primary mouse osteoblasts and MC3T3-E1 cells were grown to confluence. The medium was then changed to differentiation medium (with 100 mg/ml ascorbic acid, 5 mM b-glycerol phosphate and 10% FBS) with and without dasatinib. The medium was changed every 3 days. Alkaline phosphatase activity in the cell extracts was measured using p-Nitrophenyl Phosphate Liquid Substrate System (Sigma, St Louis, MO, USA) and the absorbance was determined at 405 nm. Osteocalcin in the conditioned medium was detected by performing a mouse osteocalcin enzyme-linked immunosorbent assay (ELISA; Biomedical Technologies, Stoughton, MA, USA). Von Kossa staining for mineralized bone matrix was carried out as described elsewhere (Bhargava et al., 1988) . Osteonectin in the conditioned medium was determined by western blot as described elsewhere (Chen et al., 2007) .
Osteoclast assays
Primary mouse osteoblasts or RAW264.7 cells were plated 10 000 cells per well in 96-well plate. The following day, cells were treated with RANKL (10-100 ng/ml). After incubation at 37 1C for 96 h, TRAP activity in the culture supernatants was measured and the cells were processed for TRAP staining using TRAP Staining kit (Kamiya Biomedical Company, Seattle, WA, USA).
Immunoprecipitation and western blot analyses
Proteins from PMOs and MC3T3-E1 cells untreated or treated with dasatinib were subjected to 4-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins in the gel were transferred onto nitrocellulose membranes and blotted with antibody against anti-p-SFK (rabbit anti-p-Src-416; Calbiochem, San Diego, CA, USA). Tubulin and actin levels, detected by anti-a-tubulin or anti-actin antibody (both from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), were used as loading control. The expression of Src, Lyn, Yes and Fyn in MC3T3-E1 cells was determined by immunoprecipitation of total cell lysate with antibodies against Src and Lyn (both from Santa Cruz Biotechnology Inc.), Yes (Wako, Richmond, VA, USA) and Fyn (Alexis, San Diego, CA, USA), respectively, followed by western blotting with anti-p-SFK (Santa Cruz Biotechnology Inc.) antibody. Blots were further immunoblotted with antibodies against each tyrosine kinase to confirm the efficacy of immunoprecipitation. The expression of Abl in PMOs or MC3T3-E1 cells was determined by western blotting of total cell lysate with anti-Abl antibody 8E9 (Upstate, Charlottesville, VA, USA) or by immunoprecipitation of cell lysate with anti-Abl antibody K12 (Santa Cruz Biotechnology Inc.) followed by western blotting with anti p-Y245-c-Abl antibody (Cell Signaling, Danvers, MA, USA). All antibodies used in this study have been shown to react with the corresponding mouse and human proteins.
Knockdown of Src or Abl in PMOs
Primary mouse osteoblasts were plated at 50 000 cells per well in a 24-well plate. After overnight incubation, the cells were infected with lentiviral particles containing shRNAs for Src, Abl or control nontargeting shRNA (Santa Cruz Biotechnology Inc.) at a ratio of 2.5 infectious units per cell. PMOs infected with copGFP lentil particles (Santa Cruz Biotechnology Inc.) were used as a control for viral infection. After 24 h, the virus-containing medium was removed and replaced with a-MEM medium containing 10% FBS. The cells were allowed to grow to confluence for 3 days and the medium was changed to differentiation medium. The conditioned medium was collected every 3 days and the cell lysates were collected at days 9 and 18. Von Kossa staining of differentiated PMOs was performed on day 18.
Protein concentration determination
Protein concentrations were measured by testing 10 ml of each sample in 200 ml of Coomassie Plus Protein Assay Reagent (Thermo Scientific, Waltham, MA, USA), using BSA as the protein standard. The reaction was performed in a 96-well microtiter plate, and the color was read at 595 nm.
Statistical analyses
Statistical analysis of the data was performed using two-tailed, paired Student's t-test. A P-value of less than 0.05 was considered statistically significant. Data are expressed as the means±s.d.
